Boehringer agrees to comply with CMS’ price negotiations over blockbuster Jardiance

Boehringer In­gel­heim said Wednes­day that it will take part in the first round of price ne­go­ti­a­tions with the Cen­ters for Medicare and Med­ic­aid Ser­vices for its block­buster type 2 di­a­betes drug Jar­diance (em­pagliflozin).

“We are com­mit­ted to en­gag­ing in open and trans­par­ent con­ver­sa­tions with CMS,” the com­pa­ny said in a writ­ten state­ment to End­points News. “We look for­ward to shar­ing de­tailed in­for­ma­tion with CMS on the val­ue of Jar­diance and to re­in­force the need to in­vest in sci­en­tif­ic med­ical in­no­va­tion for the pa­tients we serve.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.